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Abstract
Background: Distinct characteristic features categorize Merkel cell carcinoma (MCC) into two subgroups according
to the Merkel cell polyomavirus infection. Many mutational studies on MCC have been carried out in recent years
without identifying a prominent driver mutation. However, there is paucity reporting the expression of cancer
genes at the RNA level in MCC tumors. In this study, we studied the RNA expression profiles of 26 MCC tumors,
with a goal to identify prospective molecular targets that could improve the treatment strategies of MCC.
Methods: RNA expression of 50 cancer-related genes in 26 MCC tumors was analyzed by targeted amplicon based
next-generation sequencing using the Ion Torrent technology and the expression compared with that of normal,
non-cancerous skin samples. Sequencing data were processed using Torrent Suite™ Software. Expression profiles of
MCV-negative and MCV-positive tumors were compared. Fluorescence in situ hybridization was performed to study
ALK rearrangements and immunohistochemistry to study ALK expression in tumor tissue.
Results: ALK, CDKN2A, EZH2 and ERBB4 were overexpressed, and EGFR, ERBB2, PDGFRA and FGFR1 were
underexpressed in MCC tumors compared to normal skin. In the MCV-negative tumors, MET, NOTCH1, FGFR3, and
SMO were overexpressed and JAK3 and NPM1 were under-expressed compared to the MCV-positive tumors.
Conclusions: High expression of ALK, CDKN2A and EZH2 was recorded in MCC tumors. No ALK fusion was seen by
FISH analysis. Overexpression of EZH2 suggests its potential as a drug target in MCC.
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Background
Merkel cell carcinoma (MCC) is a neuroendocrine skin
tumor with a high potential to metastasize. UV-radiation
and Merkel cell polyomavirus (MCV) infection contrib-
ute to oncogenesis in MCC. [1] The viral oncogenic
pathway accounts for the large majority of MCC tumors,
as 80% of the tumors are MCV-positive. [2] Cumulative
evidence suggests two MCC subgroups with and without
MCV infection. [3–7].
Clonal integration of the MCV DNA into the tumor cell
genome as well as mutations in the viral Large T Antigen
enable oncogenic transformation in MCV-positive MCC.
[2, 8] The non-viral pathway preceding MCV-negative
MCC is less understood. Recent studies show that MCV-
negative MCC tumors have a much higher mutational
burden than MCV-positives. However, none of the earlier
studies on driver mutations in MCV-negative tumors have
succeeded in identifying prominent mutation. [9–13]
While many mutational studies concerning MCC have
been carried out in recent years, little is known about the
expression of cancer genes at the RNA level.
In the current study, we aspired to examine the RNA
expression of 50 known cancer genes in MCC tumors.
We used targeted next-generation sequencing to assess
the RNA expression profiles of both MCV-positive and
MCV-negative tumors. The fundamental aim of our
study is to find potential molecular targets to improve
the treatment strategies of MCC.
Methods
The Ethics Committee of Helsinki University Hospital
approved the study and its plan. The Ministry of Health
and Social Affairs granted permission to collect patient
data, and the National Authority for Medicolegal Affairs
to collect and analyze tissue samples.
* Correspondence: tuukka.veija@helsinki.fi
1Department of Pathology, Faculty of Medicine, University of Helsinki,
Haartmaninkatu 3, P.O. Box 21FI-00014 Helsinki, Finland
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Veija et al. BMC Cancer  (2017) 17:236 
DOI 10.1186/s12885-017-3233-5
From our pool of 270 formalin-fixed paraffin-embedded
(FFPE) MCC tumor samples, we chose 13 MCV-negative
and 13 MCV-positive tumors based on known MCV status
and sufficient tumor sample available. MCC diagnoses were
confirmed by morphology compatible with MCC in mi-
croscopy and by immunohistochemistry positive for CK-20
and negative for TTF-1. All tumor samples contained at
least 50% of tumor tissue.
Patients
Twenty-six patients with a primary MCC tumor were in-
cluded in this study, 19 females and 7 males. The mean
age of the patients was 79 years (range 59–100). The
mean tumor size was 33 mm. The study group was
divided into two subgroups based on the MCV status of
the tumor samples. The MCV status was determined as
described in our previous study. [14] Clinical data of the
patients are presented in Table 1.
RNA extraction
The total RNA was extracted from MCC tumor samples
and two normal control skin samples. Extraction was
performed according to the manufacturer’s manual using
the miRNeasy mini Kit (Qiagen, Hilden, Germany).
Qubit 2.0 Fluorometer (Thermo Fisher Scientific) and
2200 TapeStation System in combination with RNA
ScreenTape assay (Agilent Technologies, Santa Clara,
CA, USA) was used to measure the quantity and the
quality of the RNA.
Targeted next-generation sequencing
Quantitative RNA expression analysis was performed
by amplicon-based next-generation sequencing (NGS)
using Ion Torrent technology (Thermo Fisher Scientific,
Waltham, MA, USA). The Ion AmpliSeq™ RNA Library
Kit (Thermo Fisher Scientific, Waltham, MA, USA) was
used to construct the libraries from 20 ng of RNA. RNA
was reverse transcribed, and targeted regions of RNA were
Table 1 Clinical data and ALK results
No MCCa MCV age Tumor location Tumor size mm ALK NGSb ALK IHC D5F3 5A4 ALK FISHc
1 P2 pos < 80 Right cheek + + − −
2 P3 pos ≥ 80 Posterior thigh 85 + + − +
3 P4 pos < 80 Thorax 70 + + − −
4 P5 pos < 80 Right knee 12 + + −
5 P9 pos ≥ 80 unknown 20 + + + −
6 N10 neg ≥ 80 Right arm 50 + + + +
7 N11 neg ≥ 80 Left temple 15 − – – −
8 P12 pos ≥ 80 Forehead 40 + + − −
9 P13 pos < 80 Right buttock 34 + + − −
10 P14 pos ≥ 80 Left cheek 18 + + − −
11 N17 neg < 80 Right cheek 20 + + − −
12 N18 neg < 80 Right breast 20 + + −
13 N19 neg < 80 Calf 13 + + −
14 N21 neg < 80 Neck 25 + + − –
15 P23 pos < 80 Left forearm 40 + + − −
16 N25 neg ≥ 80 Left back + + − +
17 P26 pos ≥ 80 Right shoulder 24 + + − −
18 P28 pos ≥ 80 Left arm 75 + −
19 N29 neg ≥ 80 Back 75 − – – −
20 N31 neg < 80 Left foot 10 + + + −
21 N32 neg ≥ 80 Right breast 23 − (+) – −
22 N33 neg ≥ 80 Front of left ear 18 − (+) – −
23 P34 pos < 80 Flank 20 + + + +
24 N35 neg < 80 Upper abdomen 25 + + − −
25 P36 pos < 80 Right buttock 30 + −
26 N37 neg ≥ 80 Right cheek 30 + + − +
aMCC tumor number. bCases that had high expression of ALK by NGS are marked +. cTumors with 3 or more dual signals in FISH are marked +. In cases N32 and
N33, low proportion of tumor cells stained positive with D5F3 and thus are marked (+)
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PCR amplified using the Ion AmpliSeq™ RNA Cancer
Panel (Thermo Fisher Scientific, Waltham, MA, USA)
consisting of specific primers sets to amplify 50 target
genes. (Additional file 1: Table S1) The Amplicons were
then partially digested, and barcode adapters were ligated
with the Ion Xpress™ Barcode Adapter Kit (Thermo Fisher
Scientific, Waltham, MA, USA) to yield a barcoded
library. Library concentrations were measured using the
Qubit 2.0 Fluorometer (Thermo Fisher Scientific,
Waltham, MA, USA).
Templates for sequencing were prepared using the Ion
PGM™ Hi-Q™ OT2 Kit (Thermo Fisher Scientific) and Ion
OneTouch™ 2 System (Thermo Fisher Scientific, Waltham,
MA, USA). Ion Sphere™ particles were enriched with Ion
OneTouch ES (Thermo Fisher Scientific, Waltham, MA,
USA) and loaded onto an Ion 318™ Chip (Thermo Fisher
Scientific, Waltham, MA, USA).
Sequencing was performed on the Ion Torrent PGM™
System using the Ion PGM™ Hi-Q™ Sequencing Kit
(Thermo Fisher Scientific, Waltham, MA, USA).
Data analysis
Sequencing data was processed using Torrent Suite™
Software. The Coverage Analysis plugin was used to cre-
ate amplicon counts. The mean length of amplicons was
150 bp. The amplicon count data created was imported
into a Chipster [15] (http://chipster.csc.fi/index.shtml)
for further differential gene expression analysis. Differen-
tial expression analysis, to compare expression differ-
ences between tumor and normal skin tissue and
between MCV-positive and MCV negative tumors, was
performed on read count data carried out with DESeq2.
Differently expressed genes were determined from ad-
justed p-values and log2 fold change. To control for false
positives, the p-values were corrected for multiple testing
and the adjusted p-value or FDR (false discovery rate) cal-
culated using Benjamini-Hochberg correction. An average
of 344,458 reads (after quality check) were obtained for
each sample with an average of 95% on target.
ALK Immunohistochemistry
The sections (3 μm) were stained with fully automated
immunostainer Ventana Benchmark XT (Roche/Ventana,
Tucson, AZ, USA). For both ALK antibodies we used
heat- induced epitope retrieval buffer Cell Conditioning 1
(Roche/Ventana, 950–124) for 64 min in 98 °C. The dilu-
tions and incubation times for ALK antibodies were: clone
5A4 (Novocastra™, Leica Biosystems, Wetzlar, Germany)
1:100 for 40 min/36 °C and clone D5F3 (Ventana/Roche,
Tucson, AZ, USA) 28 min/36 °C. The three- step, mul-
timer based detection kit, OptiView (760–700, Roche/
Ventana), was used to detect the antibodies. Amplifica-
tion step was added for both protocols by using separated
amplification kit (Roche/Ventana, 760–099). The slides
were finally stained with hematoxylin (Mayer, S3099,
Dako, Glostrup, Denmark). For the control of the staining
quality we used skin, appendix and known ALK positive
and ALK negative tumor tissue. The stained slides were
examined by researchers TB, TV, MK and VKS.
Fluorescence in situ hybridization (FISH)
FISH was performed on 2 μm thick FFPE tumor sec-
tions. The sections fixed on microscopic slides were
de-paraffinized, pre-treated with protease and hybrid-
ized with Vysis LSI ALK Dual Color Break Apart FISH
probes according to the vendor’s guidelines (Abbott
Molecular Inc., Des Plaines, IL, USA) and as described
previously. [16] Results were checked under a fluores-
cence microscope. The criteria for considering a cell
to be ALK gene rearrangement positive was: presence
of at least one green and orange signal pair split
apart by ≥2 signal diameters (pair-signal type fusion),
or a single orange without corresponding green signal
(single-signal type fusion). The cells were considered
ALK fusion negative if they had fused or if they had
close orange and green signal.
Results
MCC vs non-cancerous tissue
Gene expression of all 26 MCC tumor samples compared
to that of normal skin samples showed eight significantly
(p-value <0.005 and log2 fold change of at least 2) differ-
ently expressed genes by DEseq2 (Table 2). Overexpres-
sion of ALK, CDKN2A, EZH2 and ERBB4 was recorded in
MCC samples compared with normal skin samples.
Downregulation of EGFR, ERBB2, PDGFRA and FGFR1
was evident in MCC tumors compared with normal skin
samples (Fig. 1).
ALK was the most significantly overexpressed gene in
tumor tissue of MCC patients, with a log2fold change of
7.6. ALK expression was absent or very low in normal skin;
a normalized read count of 0 and 19 in normal skin
compared to a mean normalized read count of 4549 (range
71–16,090; >1000 in 22/26) in tumor samples (Fig. 2). In
Table 2 RNAs with differential expression in MCC tumors
compared with normal skin as analyzed by DESeq2
Gene log2FoldChange p-value adjusted p-value
ALK 7,6 1,21E-16 6,03E-15
CDKN2A 4,4 1,10E-11 2,74E-10
EZH2 2,7 2,45E-07 4,08E-06
EGFR -4,8 2,56E-06 3,20E-05
ERBB2 -3,7 6,10E-05 0,0006104
FGFR1 -2,9 0,0002632 0,002194
PDGFRA -3,6 0,0007482 0,005344
ERBB4 2,5 0,006786 0,04241
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Fig. 1 Differently expressed genes in MCC tumors (N: MCV-negative, P: MCV-positive) compared to normal skin tissue (A and B). Upper panel
shows normalized expression of all statistically overexpressed genes (ALK, EZH2, CDKN2A and ERBB) and lower panel shows expression of all
underexpressed genes (EGFR, PDGFRA, ERBB2 and FGFR1) in MCC compared with normal skin
Fig. 2 Normalized RNA expression of ALK, its correlation with its protein expression as studied by immunohistochemistry (Clone D5F3) and DNA
alterations (copy number) as seen by FISH in MCC tumors (N: MCV-negative, P: MCV-positive) and normal skin (A and B)
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order to see whether ALK was also expressed at protein
level, we performed immunohistochemistry on tumor and
normal skin tissue sections using two different antibodies.
We also performed FISH on sections to investigate
whether increased expression was related to any genetic al-
terations involving ALK (Fig. 2). ALK immunohistochemis-
try was positive in 22 MCC tumors with antibody clone
D5F3 and in four tumors with clone 5A4. All ALK positive
tumor samples by IHC also showed high RNA expres-
sion. Both the normal skin samples and normal skin
around the tumors were negative for ALK. IHC stainings
are illustrated in Fig. 3.
Fluorescence in situ hybridization
FISH results were obtained from 21 tumor samples and
2 normal skin samples. For the remaining tumors, the
signals were too weak to get any reliable results, and
thus were not included in the FISH analysis.
We did not find any break-apart signals in any of the
tumor samples, thereby ruling out the possibility of
translocation/inversion. However, in five samples, three
or more dual signals were seen in local regions indicat-
ing gain/polyploidy. These five samples stained positive
for ALK in IHC with clone D5F3 and two of these sam-
ples were also positive with clone 5A3. ALK expression
by NGS, IHC and FISH results are presented with the
clinical data in Table 1.
MCV-negative and -positive tumors
Hierarchical clustering did not separate the MCV-negative
from the MCV-positive group based on the expression of
the 50 genes. However, six genes showed statistically differ-
ential expression between the MCV- positive and - negative
groups (Table 3, Fig. 4). In the MCV-negative tumors,
MET, NOTCH1, FGFR3, and SMO were overexpressed and
JAK3 and NPM1 were under-expressed compared to the
MCV-positive tumors.
Discussion
In this study, we analyzed the RNA expression of 50
cancer-related genes in 26 MCC tumors by targeted
next-generation sequencing and compared their expres-
sion with normal, non-cancerous skin samples. Among
the 50 cancer-related genes, we identified eight genes
(Table 2) that had differential expression in tumor tissue.
Further confirmation of the results with quantitative
PCR in larger tumor cohort and comprising more genes
is required.
We recorded overexpression of cancer related genes
including ALK, CDKN2A, and EZH2 compared with
normal skin. Among the under-expressed genes, we
identified EGFR, in concordance with our earlier study
showing negative EGFR expression by immunohisto-
chemistry in MCC tumors. [9] Earlier studies have found
inactivating RB1 and TP53 mutations driving MCV-
negative tumors, [10] however we did not find different
A B
C D
Fig. 3 ALK Immunohistochemistry in MCC tumor samples. a: negative ALK IHC (Clone 5A4) in MCC tumor sample (Sample N18, 200×
magnification). b: positive ALK IHC (Clone 5A4) in MCC tumor sample (Sample N10, 200× magnification). c: negative ALK IHC (clone D5F3) in MCC
tumor sample (Sample N29, 200× magnification). d: positive ALK IHC (Clone D5F3) in MCC tumor sample (Sample N10, 200× magnification)
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expression of RB1 or TP53 in MCV-negative tumors
compared to MCV-positive tumors.
In this study, we recorded for the first time ALK over-
expression in tumors of MCC patients. ALK expression
was seen in all patients with high levels in 22/26 tumor
samples (Table 1, Fig. 2). ALK overexpression at the
mRNA level seen in our results fits well with the protein
expression results of the only ALK IHC study on MCC
[17], whereby they demonstrated ALK expression in 30/
32 MCC tumors by one (clone D5F3) of the three anti-
bodies used in the study. They however noted that the
frequency of ALK positive cases for MCC tumors
depended a lot on the antibody used and found ALK
positivity in 4/32 with the ALK1 clone and 28/32 with
clone 5A4. In our IHC analysis we used the clones D5F3
and 5A4. Positive results were seen in 22/24 (Clone
D5F3) and 4/26 (Clone 5A4) tumors, and only in those
that had a high RNA expression. IHC staining was more
even and vivid with clone D5F3 (Fig. 3). Therefore, our
results correspond well with the previous ALK IHC
study and it seems that clone D5F3 is the most sensitive
clone in detecting ALK expression in MCC tumors.
ALK is normally expressed predominantly in central
nervous system and it likely functions in development of
the brain. ALK is however, known mainly for its role in
Table 3 RNAs with differential expression in MCV-negative
tumors compared to MCV-positive as analyzed by Deseq
deseq NvsP log2FoldChange p-value adjusted p-value
NOTCH1 1,3 9,17E-05 4,58E-03
NPM1 -1,1 2,35E-04 5,88E-03
FGFR3 1,6 3,97E-04 6,62E-03
MET 1,9 7,59E-04 9,49E-03
JAK3 -1,6 3,03E-03 3,03E-02
SMO 1,5 6,38E-03 4,56E-02
Fig. 4 Normalized expression of genes differently expressed between MCV-negative and MCV-positive tumors. Light grey: normal skin tissue; dark
grey: MCV-negative tumors (N); black: MCV-positive tumors (P)
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various types of cancer. One common mechanism of
ALK activation in tumors is ALK gene rearrangement
leading to fusion protein like NPM-ALK in anaplastic
large cell lymphomas [18] and EML4–ALK in non-
small-cell lung cancer. [19]. In order to study whether
the mechanism behind the mRNA overexpression is a
fusion gene or gene amplification, we performed the
FISH analysis. As no fusions or high level amplification
(only 2–3 times gain in 5 cases) were seen by FISH, the
mechanism behind ALK overexpression might possibly
be epigenetic or as a result of over-activation of a tran-
scription factor. Similar to our results, no rearrangement
or other cytogenetic aberration of the ALK gene have
been reported in MCC. [17].
ALK expression without any rearrangement or amplifi-
cations of the ALK has, been reported in hepatocellular
carcinoma associated with poor prognosis and occur-
rence of micrometastases [20]. While no clear driving
pathway in MCC has been identified, ALK is expressed
in MCC tumors at both the RNA and protein level, and
therefore, studying the mechanism and significance of
this overexpression remains intriguing. Studying the cor-
relation between ALK expression and survival in a larger
MCC tumor cohort would be of future interest.
CDKN2A was another gene overexpressed in MCC
tumors compared to normal skin. Our results are in
concordance with our group’s previous study showing an
expression of p16 (encoded by CDKN2A) by IHC in
97.7% of 88 MCC tumors. [21] CDKN2A is frequently
mutated or deleted in a wide variety of tumors, including
malignant melanoma and MCC and is considered to be a
tumor suppressor gene. [9, 22, 23] p16 overexpression in
malignant tumors is thought to be a mechanism to over-
come proliferation resulting from the failure of the RB1
pathway due to viral infection, genetic/epigenetic silencing
of RB1 gene or other mechanism. [24] p16 overexpression
is additionally reported in HPV infection associated cer-
vical dysplasia and carcinoma as well as in cervical neuro-
endocrine tumors. [25–27] In MCC, CDKN2A RNA
expression and p16 protein expression were, however,
independent from the tumors’ MCV-status, although the
role of RB1 in MCC is reported earlier. [28].
The expression profile of MCC tumors also showed
overexpression of EZH2 that codes for an enzyme im-
portant in heterochromatin formation via DNA methyla-
tion. Mutations or overexpression of EZH2 are seen in
many forms of malignancies. [29, 30] It is thought that
overexpression of EZH2 inhibits the transcription of
tumor suppressors, thus promoting malignant trans-
formation. Inhibitors of EZH2 are in development, and
their role in cancer treatment is being studied. In malig-
nant melanoma, Zingg et al. recently found that EZH2
expression correlated with poor survival and promotes
the initiation and progression of melanoma in mouse
models as well as human cell cultures. Using both an
RNA interference and preclinical drug GSK305 to target
EZH2, they showed that EZH2 could be a promising
therapeutic target in the treatment of melanoma pa-
tients. [31] To our knowledge, EZH2 expression is not
previously reported in MCC tumors. It could be that
EZH2 transcriptionally silences important tumor sup-
pressors in MCC, similarly to its function in melanoma.
Studying the role of the overexpression of EZH2 in
MCC oncogenesis would be of interest as a drug target.
Comparison of gene expression among the MCV –
negative and positive groups showed a higher expression
ofMET, SMO, FGFR3 and NOTCH1 in MCV-negative tu-
mors compared to MCV positive tumors.MET is a known
target of microRNA-34a, and in our previous study, we
had reported under-expression of this miRNA in MCV-
negative MCC. [7]. Notably, two genes, JAK3 and NPM1
were overexpressed in MCV-positive tumors compared to
MCV-negative. JAK3 is predominantly expressed in im-
mune cells. To our knowledge, JAK3 mutations have not
been reported in MCC. Activating JAK3 mutations are
seen in hematological malignancies. Deficiency/defects in
JAK3 leading to low amounts of functional protein are as-
sociated with immune dysfunction/immunodeficiency.
[32] NPM1 is involved in many processes and is a fusion
partner with many genes, especially ALK. Overexpression
of NPM1 is reported in many tumors including HCC,
colon cancer and glioblastoma. [33–36]. NPM1 associates
with viral proteins of different viruses and is implicated in
various stages of viral infection. [37], and this might be a
reason for its higher levels seen in MCV-positive tumors.
The significance of the genes differentially expressed
between the MCV-negative and positive groups is how-
ever not clear and needs further investigation.
Conclusions
We established that ALK is overexpressed in MCC tu-
mors, although no ALK fusion was seen by FISH analysis.
Thus significance of ALK in MCC remains uncharted, yet
intriguing. Overexpression of EZH2 suggests its potential
as a drug target in MCC.
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